MedTrace Logo

A Trial of SHR-1703 in Healthy Subjects

NCT04855591 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-12-01

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy subjects.

Conditions

Interventions

DRUG

SHR-1703

SHR-1703 will be administered subcutaneously

DRUG

Placebo

Placebo of SHR-1703 will be administered subcutaneously

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Dr Richard Friend · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-14
Primary Completion
2021-09-13
Completion
2021-11-18

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855591 on ClinicalTrials.gov